NVP-BEP800
NVP-BEP800, also known as BEP-800, is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 showed activity against a panel of human tumor cell lines and primary human xenografts in vitro at nanomolar concentrations. In A375 melanoma and BT-474 breast cancer cell lines, NVP-BEP800 induced client protein degradation (including ErbB2, B-Raf(V600E), Raf-1, and Akt) and Hsp70 induction.
Supplier | Alfa Cytology |
---|---|
Product # | BC0263 |
Pricing | 100.0 mg, 200.0 mg, 500.0 mg, 1.0 g, 2.0 g, inquire |